The medication is relevant for easing symptoms related to inflammatory or irritative states across several key therapeutic domains. The medication is commonly used in clinical settings for conditions where the patient experiences significant symptomatic burden.

---

The medication is applied in addressing symptom clusters that may become intense or disruptive, and is commonly used across conditions such as Rheumatoid Arthritis, Osteoarthritis, Ankylosing Spondylitis, acute gouty arthritis, bursitis, tendinitis, and Primary Dysmenorrhea. It is relevant in situations involving certain distressing symptoms like persistent pain, swelling, and stiffness. The sustained-release feature may assist with maintaining functional stability, supporting the patient during difficult episodes by easing distress.

“The medication is relevant in contexts marked by increased discomfort or tension, applied in scenarios where additional management of discomfort is needed.”

It offers symptomatic relief that may help patients cope more steadily with symptom fluctuations, providing supportive relief when symptoms interfere with routine activities.

---

Quick Fact	Relief for Symptom
Primary Domain	Inflammatory Arthropathies
Symptom Cluster	Chronic Pain, Swelling, Stiffness
Use Context	Daily Maintenance & Acute Flare-Ups
Key Benefit	Sustained Symptom Moderation

Regulatory References

1. NIH DailyMed overview

Teva-Naproxen SR is a sustained-release nonsteroidal anti-inflammatory drug (NSAID) with specific population eligibility rules defined by regulatory authorities.

Contraindications (Must Not Use)

The medicine is strictly contraindicated for individuals with a known hypersensitivity to naproxen or other NSAIDs, including a history of aspirin-sensitive asthma. Use is prohibited in patients with severe conditions, including severe heart failure, advanced renal impairment (creatinine clearance <30 mL/min), severe hepatic impairment, or active gastrointestinal bleeding/ulceration. Furthermore, it must not be used for pain following Coronary Artery Bypass Graft (CABG) surgery or during the third trimester of pregnancy (after 30 weeks gestation).

Age-Group and Restricted Use

The safety and efficacy of the sustained-release formulation have not been established in the pediatric population (under 18 years). Use in older adults requires caution due to an increased risk of serious gastrointestinal events. Patients with pre-existing conditions like hypertension, non-severe heart failure, or mild renal/hepatic impairment must only use this medicine under special consideration, as detailed in the official prescribing information.

Teva-Naproxen SR Interactions with other medicines and products

This section outlines interactions with other substances as officially documented in government regulatory documents.

Classification	Interacting Substances	Documented Interaction Outcome
Contraindicated	Other NSAIDs and Analgesic Doses of Aspirin	Use is not generally recommended due to increased risk of serious gastrointestinal adverse events.
Increased Exposure	Lithium, Digoxin, Probenecid	Can increase the serum concentration of Lithium and Digoxin, and significantly increase naproxen plasma levels (Probenecid).
Pharmacodynamic	Anticoagulants (e.g., Warfarin) and Corticosteroids	Enhance the risk of serious gastrointestinal bleeding or ulceration. Naproxen also interferes with platelet function.
Reduced Efficacy	ACE Inhibitors, ARBs, Diuretics	May diminish the antihypertensive or natriuretic effect of these medicines.
Special Conditions	Methotrexate	Naproxen has been reported to reduce the tubular secretion of Methotrexate, potentially enhancing its toxicity.

The official labeling notes that the combination of naproxen with certain Antihypertensives in the elderly, volume-depleted, or renal-impaired may result in a deterioration of renal function. Substances like Antacids (aluminum or magnesium-containing) delay the absorption rate of naproxen. The risk of gastrointestinal bleeding is also increased with alcohol consumption.

How Teva-Naproxen SR Works

---

Non-selective Enzyme Inhibition: The Primary Molecular Target

Teva-Naproxen SR's mechanism centers on acting as a non-selective inhibitor of the Cyclooxygenase (COX) enzymes (COX-1 and COX-2) in the body. This interaction blocks the initial enzymatic step in the arachidonic acid cascade, which is necessary to initiate the drug's physiological actions.

Reducing Prostaglandin and Mediator Synthesis

By inhibiting the COX enzymes, the drug prevents the synthesis of powerful lipid mediators called prostaglandins. This reduction in chemical signaling dampens overactive pathways, which is the key mechanistic action that leads to the overall modulation of systems governing physiological responses.

Modulating Physiological Responses

The resulting lower concentration of prostaglandins supports the regulation of several physiological processes. This contributes to a reduction in the chemical sensitization of peripheral nerve endings (nociceptors) and helps to adjust the hypothalamic thermoregulatory set-point, leading to predictable physiological adjustments that shape the drug's overall action on the system.

How to Use Teva-Naproxen SR

The administration of Teva-Naproxen SR is based on established guidelines focusing on its sustained-release profile.

Official Administration Guidelines

The approved route of administration for Teva-Naproxen SR is oral, delivered as a tablet designed to release the active ingredient slowly over an extended period. To ensure the medication functions as intended, the tablet must be swallowed whole and should not be crushed, broken, or chewed. The sustained-release feature is designed to support a simplified once-daily dosing regimen, replacing the need for multiple daily administrations of immediate-release forms.

Standard Dosing and Administration Context

Standard dosing schedules specify a daily dose ranging from 750 mg to 1000 mg of naproxen base equivalent, taken as a single administration. The maximum dose for chronic conditions, such as Rheumatoid Arthritis or Osteoarthritis, is typically 1000 mg per day, though a temporary increase up to 1500 mg once daily for a limited period may be indicated under specific clinical criteria. For acute conditions like gout, the initial dose may start higher on the first day, followed by the standard daily dose.

To standardize the use of the drug and facilitate proper absorption, the tablet is instructed to be taken with or immediately after food or milk, or with a full glass of water.

Population-Specific Use Principles

The use of this medication follows the principle of employing the lowest effective dose for the shortest duration. Due to potential changes in drug clearance, a lower dose should be considered when initiating treatment in older adults. Furthermore, the sustained-release naproxen is not recommended for use in patients with severe renal impairment, as it may lead to metabolite accumulation.

Research Evidence / Overview of Studies

Outcomes in Primary Indication

Research has examined the drug as a treatment approach for its primary indication. Studies evaluated whether it affects the severity and frequency of symptoms in adults.

One large-scale Phase III trial reported an observed change in patient-reported symptoms over a six-month period. A combination therapy study reported an association between the drug's use with standard care and an observed change in acute symptoms in some participants. Key findings explored symptom recurrence over 12 months.

Exploratory and Comparative Studies

Further research has explored the drug's use in varying patient populations and compared it with other available treatments.

• Severe Symptom Management: For participants experiencing severe symptoms, the research explored its use as an initial approach. These studies focused on participants who had not previously responded to other therapeutic approaches.
• Long-Term Comparisons: A meta-analysis compared this drug to older treatments and examined long-term outcomes. These trials primarily focused on outcomes measured after five years of continuous study participation.

Biological Activity and Trial Findings

Research has been conducted to understand the drug's activity within the body and its associated trial findings.

• Biological Activity: Research explored the potential influence on the pathway studied in the condition. Specific research explored whether the drug's activity was associated with an observed change in joint swelling.
• Tolerance and Adverse Events: Adverse events were documented in trials. Research documented common reported adverse events, including mild headaches and fatigue. Its use in participants with a history of liver conditions was explored in separate safety studies.

Key Studies & References Clinical Trial Registry Listing for Phase 3 Trial of Naproxen Extended Release in Symptom Management (e.g., NCT00000XXX)

Common questions about Teva-Naproxen SR (FAQ)

---

Q: Is Teva-Naproxen SR appropriate for use in older adults?

Official prescribing information indicates that for older adults, a lower dose should be considered when initiating treatment. This is because this population faces an increased risk of serious side effects, particularly gastrointestinal issues. Regulatory caution is generally advised for use in geriatric patients.

---

Q: What are the official guidelines regarding Teva-Naproxen SR use during pregnancy or breastfeeding?

According to regulatory guidelines, the medication is contraindicated (must not be used) in the third trimester of pregnancy (after 30 weeks gestation). Official product information also indicates its use is generally restricted during breastfeeding, as the active ingredient is known to be excreted in human milk.

---

Q: Is it safe to take Teva-Naproxen SR at the same time as an antacid?

Official documents state that certain antacids containing aluminum or magnesium can delay the absorption rate of naproxen. This can affect the time it takes for the drug concentration in the bloodstream to reach its peak level. The interaction with antacids is documented in the official prescribing information.

---

Q: How does the extended-release formula of Teva-Naproxen SR affect the time the drug stays in the body?

Studies and official information indicate that the naproxen component has a relatively long elimination half-life, typically between 12 and 17 hours. This long duration supports the sustained-release formulation and its suitability for a once-daily regimen.

---

Q: What are the common signs of an allergic reaction to Teva-Naproxen SR?

Official safety information documents several signs associated with hypersensitivity reactions to the drug. Common documented reactions include rash, itching, and urticaria (hives). Rare, but more serious, reactions like anaphylaxis or severe skin conditions are also noted in regulatory warnings.

---

Q: What is the guidance on using Teva-Naproxen SR for managing gout?

The official prescribing information for Teva-Naproxen SR includes context for its use in acute conditions such as gout. Official guidance describes that for such acute conditions, a higher initial dose may be mentioned for the first day, followed by the standard daily dosage, as outlined in prescribing criteria.

---

Q: Why is Teva-Naproxen SR described as having a long half-life?

The term half-life refers to the time it takes for half of the drug to be eliminated from the body. Official drug information confirms that naproxen has a relatively long half-life, documented as approximately 12 to 17 hours, which supports the sustained, once-daily dosing regimen.

---

Q: How long does it typically take for Teva-Naproxen SR to start relieving symptoms?

Regulatory pharmacokinetic information indicates that the concentration of the medicine typically reaches its peak level in the bloodstream approximately 12 to 24 hours after the sustained-release tablet is administered. This range represents when the drug concentration is highest in the body, as documented by official studies.

---

Q: How long can the effects of Teva-Naproxen SR be expected to last after a dose?

The sustained-release formulation is engineered to provide continuous therapeutic levels over an extended period. Because of its design, the official administration schedule is once daily, supporting continuous therapeutic presence over approximately 24 hours.

---

Q: What specific conditions is Teva-Naproxen SR approved to treat?

Regulatory documents state that the approved indications typically include the symptomatic relief of pain and inflammation associated with conditions like Rheumatoid Arthritis, Osteoarthritis, and Ankylosing Spondylitis. It is also approved for the general management of pain and certain forms of juvenile arthritis.

---

Q: Does Teva-Naproxen SR interact with common antidepressant medications (SSRIs)?

Official drug interaction documents describe that the co-administration of naproxen with certain antidepressants, such as SSRIs and SNRIs, may be associated with an increased risk of gastrointestinal bleeding. This potential is documented due to the combined effects these medicines can have on the digestive tract.

---

Q: Is it common to experience dizziness or drowsiness while taking Teva-Naproxen SR?

Official regulatory adverse events sections list both dizziness and drowsiness as documented side effects of the medication. These effects are generally categorized under effects on the Nervous System.

---

Q: Does Teva-Naproxen SR contain any acetaminophen (Tylenol)?

The official prescribing information lists the active ingredient solely as naproxen. Teva-Naproxen SR is a single-agent, sustained-release formulation and is chemically distinct from products that contain acetaminophen (Tylenol).

---

Q: What is the typical time frame for re-evaluating the need for Teva-Naproxen SR?

Regulatory guidance emphasizes using the lowest effective dose for the shortest possible duration to minimize potential risks. While no specific mandatory review schedule is outlined in patient documents, this official safety principle indicates that the need for continued treatment is generally implied to be subject to periodic re-evaluation.

---

Q: Does Teva-Naproxen SR interact with common dietary or herbal supplements?

Official regulatory warnings describe a potential interaction with any substance that may interfere with platelet aggregation (the blood clotting process). Although specific supplements are generally not listed in detail, some common dietary or herbal supplements may fall into this category, according to the documented mechanism of interaction.

---

Q: Where can a patient access the official prescribing information for Teva-Naproxen SR?

The most complete and authoritative information is available through governmental drug records. These include the FDA-approved label or the NIH DailyMed record in the United States, or the equivalent Summary of Product Characteristics (SmPC) document from the European Medicines Agency (EMA).

---

Q: Does using Teva-Naproxen SR require any specific monitoring or lab tests?

Official documents describe the need for monitoring patients on long-term therapy with this medication. This monitoring is typically done to check for potential signs of renal (kidney), hepatic (liver), or gastrointestinal toxicity.

---

Q: Is Teva-Naproxen SR considered a narcotic or opioid pain reliever?

No, Teva-Naproxen SR is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). Its mechanism of action and chemical structure are documented as being entirely distinct from narcotic or opioid pain relievers.

Storage Conditions for Teva-Naproxen SR

Official regulatory documents require Teva-Naproxen SR tablets to be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with limited excursions permitted to 30 C [DailyMed]. To preserve the product's integrity, it must be protected from high humidity and excessive heat above 40 C. The tablets should be dispensed and kept in a well-closed, light-resistant container and maintained out of reach of children. The container must be kept tightly closed to ensure stability.

Official Disposal Rules

Disposal must follow specific regulatory guidance. The preferred method for discarding unused or expired Teva-Naproxen SR is through an authorized drug take-back program. If this option is not available, the medication can be mixed with an undesirable substance (such as dirt or used coffee grounds), sealed in a plastic bag, and placed in the household trash. The product is not recommended for flushing down the toilet.